Morning Hypertension and Monitoring of Metabolism (AWB Morgenhochdruck & Stoffwechselmonitoring)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13,248
- 主要终点
- Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP
研究概览
简要总结
To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, insufficiently treated hypertension
排除标准
- •Age < 18 years
研究组 & 干预措施
Essential hypertension
干预措施: Telmisartan (Drug)
Essential hypertension
干预措施: Telmisartan in combination with hydrochlorothiazide (Drug)
结局指标
主要结局
Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP
时间窗: Pre-dose, up to 6 months after start of treatment
Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale
时间窗: Up to 6 months after start of treatment
Changes in morning blood pressure (BP)
时间窗: Pre-dose, up to 6 months after start of treatment
Changes in metabolic laboratory parameters
时间窗: Pre-dose, up to 6 months after start of treatment
Investigator assessment of effects on metabolism on a 3-point rating scale
时间窗: Up to 6 months after start of treatment
Investigator assessment of tolerability on a 5-point rating scale
时间窗: Up to 6 months after start of treatment
Number of patients with adverse events
时间窗: Up to 6 months
Changes in morning heart rate
时间窗: Pre-dose, up to 6 months after start of treatment
次要结局
未报告次要终点